Showing results (421-430 of 466) with videos related to

Sort By:
Pageof 47
Biorxiv : the Preprint Server for Biology|June 25, 2020
Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19Carmen Mirabelli, Jesse W Wotring, Charles J Zhang, et al.
Cancer Chemotherapy and Pharmacology|May 12, 2005
Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinomaKevin T Murphy, Abdullah Wardak, Michael A Beckett, et al.
BMJ Open|September 19, 2014
The Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) study: protocol for an international multicentre randomised controlled trialMichael S Avidan, Bradley A Fritz, Hannah R Maybrier, et al.
Transplantation|March 29, 2020
Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus ConferenceNeil Mehta, Prashant Bhangui, Francis Y Yao, et al.
Hepatology (Baltimore, Md.)|January 14, 2025
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort studyEdison Xu, Parissa Tabrizian, Julio Gutierrez, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 2, 2024
Analysis of treatment benefits and prognostic factors for posttransplant HCC recurrence in a large Euro-American-Asian cohortZhihao Li, Itsuko Chih-Yi Chen, Leonardo Centonze, et al.
Gastroenterology|July 31, 2021
Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) ConsortiumNeil Mehta, Catherine Frenette, Parissa Tabrizian, et al.
Journal of Viral Hepatitis|January 17, 2025
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral TherapyAmit G Singal, K Rajender Reddy, Massimo Colombo, et al.
JAMA Cardiology|September 16, 2020
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)Neil Mehta, Ankur Kalra, Amy S Nowacki, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 20, 2021
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19Carmen Mirabelli, Jesse W Wotring, Charles J Zhang, et al.
Pageof 47